top of page
Our Pipeline
Dragonfly's novel cytokines and TriNKET® NK cell engagers can both kill cancers and other disease targets directly, and improve the outcomes of other immunotherapy approaches like T-cell therapies.
Dragonfly’s pipeline is robust and continues to grow both internally and with BMS, Merck, AbbVie, and Gilead
Phase 3
Platform
Discovery
Preclinical
Phase 1
Phase 2
Dragonfly Internal
Multiple candidates
TriNKET
DF6215
CYTOKINE
Phase 3
Platform
Discovery
Preclinical
Phase 1
Phase 2
BMS + Dragonfly Partnered
DF4001 (licensed)
TriNKET
DF5008 (licensed)
TriNKET
DF2200 (licensed)
TriNKET
Multiple candidates
TriNKET
DF2500 (licensed) - Neurology
TriNKET
Phase 3
Platform
Discovery
Preclinical
Phase 1
Phase 2
Merck + Dragonfly Partnered
DF8001 (licensed)
TriNKET
DF8101 (licensed)
TriNKET
Multiple candidates
TriNKET
Phase 3
Platform
Discovery
Preclinical
Phase 1
Phase 2
AbbVie + Dragonfly Partnered
DF4101 (licensed)
TriNKET
Multiple candidates
TriNKET
Phase 3
Platform
Discovery
Preclinical
Phase 1
Phase 2
Gilead + Dragonfly Partnered
DF7001 (5T4-targeting - licensed)
TriNKET
Multiple candidates
TriNKET
bottom of page